BACKGROUND: According to the new Dutch guideline for cardiovascular risk management, patients with a low risk of cardiovascular mortality may have insufficient benefit to warrant medication. Therefore, numerous patients per general practice may be treated unnecessarily. AIM: To explore the feasibility and consequences of a re-evaluation programme for patients without target organ damage who were treated for hypertension and/or hypercholesterolaemia. DESIGN AND SETTING: Practice-based intervention study in six general practices. METHOD: Patients treated for hypertension and/or hypercholesterolaemia without target organ damage (n = 833) were invited to re-evaluate their cardiovascular risk and were advised whether or not to stop medication. Patients who discontinued medication were followed for 6 months. To determine indicators for successful stopping, logistic regression analyses were performed, and differences between practices were analysed. RESULTS: About two-thirds of the patients were re-evaluated and 61% of them had a low calculated risk, especially younger patients, females, and non-smokers. Of these, 42% were advised to stop medication, especially younger patients and non-smokers. Of those who discontinued medication, 40% had restarted within 6 months. After 6 months, 80 of the 833 patients (9.6%) had not restarted medication. There were no important side effects related to stopping medication. CONCLUSION: Over 50% of patients without target organ damage treated for hypertension and/or hypercholesterolaemia may have insufficient benefit to warrant medication. Younger patients, females, and non-smokers in particular are more likely to have an insufficient indication for medication. GPs' and nurse practitioners' views seem to play a role in advising to stop or to restart medication.
BACKGROUND: According to the new Dutch guideline for cardiovascular risk management, patients with a low risk of cardiovascular mortality may have insufficient benefit to warrant medication. Therefore, numerous patients per general practice may be treated unnecessarily. AIM: To explore the feasibility and consequences of a re-evaluation programme for patients without target organ damage who were treated for hypertension and/or hypercholesterolaemia. DESIGN AND SETTING: Practice-based intervention study in six general practices. METHOD:Patients treated for hypertension and/or hypercholesterolaemia without target organ damage (n = 833) were invited to re-evaluate their cardiovascular risk and were advised whether or not to stop medication. Patients who discontinued medication were followed for 6 months. To determine indicators for successful stopping, logistic regression analyses were performed, and differences between practices were analysed. RESULTS: About two-thirds of the patients were re-evaluated and 61% of them had a low calculated risk, especially younger patients, females, and non-smokers. Of these, 42% were advised to stop medication, especially younger patients and non-smokers. Of those who discontinued medication, 40% had restarted within 6 months. After 6 months, 80 of the 833 patients (9.6%) had not restarted medication. There were no important side effects related to stopping medication. CONCLUSION: Over 50% of patients without target organ damage treated for hypertension and/or hypercholesterolaemia may have insufficient benefit to warrant medication. Younger patients, females, and non-smokers in particular are more likely to have an insufficient indication for medication. GPs' and nurse practitioners' views seem to play a role in advising to stop or to restart medication.
Authors: A Keys; C Aravanis; H Blackburn; F S Van Buchem; R Buzina; B S Djordjevic; F Fidanza; M J Karvonen; A Menotti; V Puddu; H L Taylor Journal: Circulation Date: 1972-04 Impact factor: 29.690
Authors: K Charalabopoulos; A Charalabopoulos; V Papalimneou; D Kiortsis; P Dimicco; O K Kostoula; G N Karachalios Journal: Int J Clin Pract Date: 2005-06 Impact factor: 2.503
Authors: M A Espeland; P K Whelton; J B Kostis; J L Bahnson; W H Ettinger; J A Cutler; L J Appel; S Kumanyika; D Farmer; J Elam; A C Wilson; W B Applegate Journal: Arch Fam Med Date: 1999 May-Jun
Authors: H Schelleman; O H Klungel; D Kromhout; A de Boer; B H Ch Stricker; W M M Verschuren Journal: J Hum Hypertens Date: 2004-05 Impact factor: 3.012
Authors: R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham Journal: Eur Heart J Date: 2003-06 Impact factor: 29.983
Authors: Linda Kok; Peter Engelfriet; Monique A M Jacobs-van der Bruggen; Rudolf T Hoogenveen; Hendriek C Boshuizen; Monique W M Verschuren Journal: Eur J Cardiovasc Prev Rehabil Date: 2009-06
Authors: Clare H Luymes; Rosalinde K E Poortvliet; Nan van Geloven; Margot W M de Waal; Yvonne M Drewes; Jeanet W Blom; Nynke Smidt; Willem J J Assendelft; Wilbert B van den Hout; Wouter de Ruijter; Mattijs E Numans Journal: BMC Med Date: 2018-01-11 Impact factor: 8.775
Authors: José Castela Forte; Pytrik Folkertsma; Rahul Gannamani; Sridhar Kumaraswamy; Sipko van Dam; Jan Hoogsteen Journal: Int J Environ Res Public Health Date: 2022-03-31 Impact factor: 3.390